OncoMatch/Clinical Trials/NCT06235151
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Is NCT06235151 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Copper Cu 64 PSMA I&T for prostate cancer.
Treatment: Copper Cu 64 PSMA I&T — This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Prior therapy
Cannot have received: androgen deprivation therapy
Androgen deprivation therapy...prior to prostatectomy
Cannot have received: neoadjuvant chemotherapy
neoadjuvant chemotherapy...prior to prostatectomy
Cannot have received: radiation therapy (including local ablation techniques)
radiation therapy (including local ablation techniques)...prior to prostatectomy
Cannot have received: investigational therapy
any investigational therapy against Prostate Cancer (PC) prior to prostatectomy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arkansas Urology · Little Rock, Arkansas
- Providence Medical Foundation · Fullerton, California
- Tower Urology · Los Angeles, California
- VA Greater Los Angeles Healthcare System · Los Angeles, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify